Clinical Trials
3
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (100.0%)A Study of Intravenous VRT106 for Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2025-02-13
- Last Posted Date
- 2025-02-13
- Lead Sponsor
- Guangzhou Virotech Pharmaceutical Co., Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT06826313
A Study of Recombinant Oncolytic Virus M1(VRT106) in Patients With Solid Tumors
- First Posted Date
- 2024-04-16
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Guangzhou Virotech Pharmaceutical Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT06368921
- Locations
- 🇨🇳
Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, China
🇨🇳Affiliated Cancer Hospital of Shandong First Medical University, Jinan, Shandong, China
🇨🇳Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
A Study of Intravenous M1-c6v1 for Locally Advanced or Metastatic Solid Tumors
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- Guangzhou Virotech Pharmaceutical Co., Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT06046742
- Locations
- 🇯🇵
National Cancer Center Hospital East, Kashiwa-shi, Chiba, Japan
🇯🇵National Hospital Organization Shikoku Cancer Center, Matsuyama-shi, Ehime, Japan
🇯🇵St. Marianna University Hospital, Kawasaki-shi, Kanagawa, Japan
News
No news found